AbbVie Inc. $ABBV Shares Purchased by Merit Financial Group LLC

Merit Financial Group LLC raised its position in AbbVie Inc. (NYSE:ABBV) by 3.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 82,042 shares of the company’s stock after buying an additional 2,461 shares during the period. Merit Financial Group LLC’s holdings in AbbVie were worth $18,996,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. 3Chopt Investment Partners LLC increased its holdings in AbbVie by 2.9% during the 3rd quarter. 3Chopt Investment Partners LLC now owns 15,379 shares of the company’s stock worth $3,561,000 after purchasing an additional 440 shares during the last quarter. Moody Lynn & Lieberson LLC grew its holdings in AbbVie by 6.4% during the 3rd quarter. Moody Lynn & Lieberson LLC now owns 183,462 shares of the company’s stock worth $42,479,000 after acquiring an additional 11,085 shares in the last quarter. Calamos Wealth Management LLC increased its position in shares of AbbVie by 74.7% in the 3rd quarter. Calamos Wealth Management LLC now owns 14,729 shares of the company’s stock worth $3,410,000 after purchasing an additional 6,298 shares during the last quarter. Calamos Advisors LLC raised its stake in shares of AbbVie by 0.3% in the 3rd quarter. Calamos Advisors LLC now owns 450,832 shares of the company’s stock valued at $104,386,000 after purchasing an additional 1,214 shares in the last quarter. Finally, Single Point Partners LLC bought a new position in shares of AbbVie during the third quarter worth about $211,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Trading Up 1.8%

ABBV opened at $231.57 on Tuesday. The business’s 50 day moving average is $223.73 and its 200-day moving average is $221.37. The stock has a market cap of $409.28 billion, a PE ratio of 98.12, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same period last year, the firm earned $2.16 EPS. The firm’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on ABBV. Scotiabank began coverage on AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price on the stock. Guggenheim increased their target price on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Citigroup reduced their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. JPMorgan Chase & Co. increased their price objective on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Finally, DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a report on Tuesday, November 4th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $251.00.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.